【摘要】：目的:本文主要通過(guò)觀察柴胡疏肝散合桃紅四物湯化裁方對(duì)肝癌TACE術(shù)后氣滯血瘀型患者AFP及臨床癥狀的影響,為原發(fā)性肝癌TACE術(shù)后氣滯血瘀型患者的提供更多治療方法。方法:將收集的60例原發(fā)性肝癌氣滯血瘀型患者,按照隨機(jī)數(shù)字表法,分成2組,每組30人,對(duì)照組給予肝癌TACE術(shù)及甘草酸二胺膠囊保肝治療,治療組在對(duì)照組的基礎(chǔ)上口服柴胡疏肝散合桃紅四物湯化裁方治療。記錄并分析兩組患者用藥前后AFP、KPS、中醫(yī)癥候的變化情況,觀察并記錄該方劑的臨床療效。結(jié)果:1.統(tǒng)計(jì)結(jié)果顯示,兩組患者AFP水平較治療前均有所降低(p0.05),治療后兩組對(duì)比顯示,治療組比對(duì)照組AFP水平降低幅度較大(p0.05);2.統(tǒng)計(jì)結(jié)果顯示,兩組患者中醫(yī)癥候及KPS較治療前均有所改善(p0.05),治療后兩組對(duì)比顯示,治療組比對(duì)照組中醫(yī)癥候及KPS改善較明顯(p0.05);3.統(tǒng)計(jì)結(jié)果顯示,兩組患者在不良反應(yīng)發(fā)生率上,治療組與對(duì)照組比較無(wú)顯著差異(p0.05)。結(jié)論:1.柴胡疏肝散合桃紅四物湯化裁方聯(lián)合肝癌TACE術(shù)能降低患者腫瘤標(biāo)志物AFP的水平。2.柴胡疏肝散合桃紅四物湯化裁方聯(lián)合肝癌TACE術(shù)能夠顯著改善患者的中醫(yī)癥候,提高患者KPS評(píng)分。3.柴胡疏肝散合桃紅四物湯化裁方對(duì)患者白細(xì)胞以及肝腎功能無(wú)不良影響。
[Abstract]:Objective: to observe the effect of Chaihu Shugan San and Taohong Siwu decoction on AFP and clinical symptoms of patients with qi stagnation and blood stasis after TACE operation of liver cancer, and to provide more treatment methods for patients with Qi stagnation and blood stasis after TACE. Methods: sixty patients with primary liver cancer with Qi stagnation and blood stasis were divided into 2 groups, 30 in each group. The control group was treated with hepatoma TACE and glycyrrhizin diamine capsule. The treatment group in the control group on the basis of oral Chaihu Shugan San Taohong Siwu decoction treatment. To record and analyze the changes of TCM symptoms of AFP,KPS, in both groups before and after medication, and to observe and record the clinical efficacy of the prescription. The result is 1: 1. The statistical results showed that the level of AFP in both groups was lower than that before treatment (p0.05). After treatment, the level of AFP in the treatment group was significantly lower than that in the control group (p0.05), and the level of AFP in the treatment group was significantly lower than that in the control group (p0.05). The statistical results showed that the symptoms of TCM and KPS were improved in both groups (p0.05). After treatment, the symptoms of TCM and KPS in the treatment group were significantly improved than those in the control group (p0.05). The results showed that there was no significant difference between the treatment group and the control group in the incidence of adverse reactions (p0.05). Conclusion: 1. Chaihu Shugan San and Taohong Siwu decoction combined with liver cancer TACE can reduce the level of tumor marker AFP. 2. Chaihu Shugan San combined with Taohong Siwu decoction combined with liver cancer TACE can significantly improve the TCM symptoms of patients and improve the KPS score of the patients. 3. Chaihu Shugan San and Taohong Siwu decoction had no adverse effect on white blood cells and liver and kidney function.
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.7

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王翔宇;;黃芪現(xiàn)代藥理及臨床研究進(jìn)展[J];科技風(fēng);2017年03期

2 朱莉紅;;紅花藥理分析及臨床應(yīng)用分析[J];中國(guó)現(xiàn)代藥物應(yīng)用;2016年16期

3 鞏瑞紅;張茂臣;張德修;;扶正健脾散結(jié)方治療原發(fā)性肝癌的臨床療效分析[J];中國(guó)實(shí)用醫(yī)藥;2015年27期

4 趙春娟;凌仕良;山廣志;;山廣志教授中醫(yī)治療肝癌經(jīng)驗(yàn)體會(huì)[J];黑龍江中醫(yī)藥;2015年01期

5 戚益銘;吳霜霜;沈敏鶴;阮善明;鄭璐;;中醫(yī)藥治療原發(fā)性肝癌研究述評(píng)[J];中醫(yī)學(xué)報(bào);2015年01期

6 徐雪琴;龍全江;趙劍;;太子參化學(xué)成分、藥理作用與產(chǎn)地加工技術(shù)研究[J];現(xiàn)代中藥研究與實(shí)踐;2014年04期

7 張利;;甘草的藥理作用及現(xiàn)代研究進(jìn)展[J];中醫(yī)臨床研究;2014年10期

8 王鋒;秦叔逵;華海清;劉秀峰;楊柳青;曲文書(shū);;含奧沙利鉑化療方案治療對(duì)索拉非尼耐藥的晚期原發(fā)性肝癌的臨床觀察[J];臨床腫瘤學(xué)雜志;2014年03期

9 儲(chǔ)真真;陳立宏;馮久桓;徐靈敏;黃祝曉;;中醫(yī)藥治療原發(fā)性肝癌研究進(jìn)展[J];中醫(yī)學(xué)報(bào);2013年10期

10 吳惠君;歐金龍;池曉玲;蕭煥明;;陳皮藥理作用研究概述[J];實(shí)用中醫(yī)內(nèi)科雜志;2013年17期

，

本文編號(hào)：2295537